When dieting, many people find themselves in a vicious cycle of starving themselves and subsequently feeling tired from lack of food, followed by taking a lot of stimulants to combat the fatigue, then being unable to sleep at night due to the stimulants, thus starting the cycle over again. Thankfully, Olympus Labs has introduced ASSASS1NATE, a dual non-stimulant fat burner + GDA, to break you out of this cycle!

How does a non-stimulant fat burner work?

Not every thermogenic is a stimulant, and ASSASS1NATE includes three non-stim ingredients, dihydromyricetin, trans-tiliroside, and carnosoic acid, that act at thermogenics and therefore increase metabolism. ASSASS1NATE doesn’t stop there though, as it also targets several other novel fat burning pathways, including PPAR-α, PPAR-γ, CPT1, and CB1 using the powerful blend of olive leaf extract, lutein, orthosiphon stamineus, and OEA.

What is nutrient partitioning?

Nutrient partitioning refers to what happens to the calories you eat, whether they are used as energy, converted to fat and stored as fat tissue, or incorporated into lean mass. ASSASS1NATE functions as a glucose disposal agent, meaning that it helps to shuttle glucose to your muscles for energy, rather than converting it to fat. However, what sets ASSASS1NATE apart from other inferior GDAs is that it does not inhibit protein synthesis, nor does it cause drops in blood sugar or hypoglycemia.

ASSASS1NATE is packed full of compounds that help you to burn fat and improve your nutrient partitioning.

Dihyrdromyricetin activates AMPK to stimulate fatty acid oxidation and glucose uptake, as well as improve the insulin resistance of skeletal muscle and regular glucose metabolism. It also stimulates irisin, which converts white adipose tissue (WAT) to brown adipose tissue (BAT), improving metabolism since BAT is more metabolically active.

Trans-tiliroside exhibits anti-obesity and anti-diabetic activities via enhancement of fatty acid oxidation in the liver and skeletal muscle, inhibiting weight gain and decreasing visceral fat. It also has PPAR- γ antagonistic properties, inhibiting lipid accumulation in white adipose tissue.

Carnosoic acid helps to stimulate metabolism, inhibit fat gain by acting as a PPAR-γ antagonist, and stimulate glucose uptake in skeletal muscle tissue.

Olive leaf extract has two components, oleuropein, which inhibits PPAR- γ and enhances thermogenesis by increasing UCP-1 in brown adipose tissue, and hydroxytyrosol, which inhibits the CB1 receptor. This means that it helps to reduce body weight gain and visceral fat.

Orthosiphon stamineus reduces appetite and visceral fat through the increase of leptin, a hormone in fat cells that regulates appetite. Sufficient levels of leptin signal the brain that there is adequate stored energy to use fat cells for metabolic purposes, but when food intake is reduced for an extended period of time, leptin levels decrease, something combated by orthosiphon stamineus.

Lutein increases CPT-1, stimulating energy metabolism. CPT-1 is an enzyme responsible for the formation of acylcarnitines, and as carnitine has lipolytic properties, this helps with fat burning,

Oleolethanolamide (OEA) is a lipid naturally occurring in the intestines of the human body that regulates appetite. Upon eating, OEA levels increase and produce a feeling of satiety. However, when caloric intake is restricted, such as when dieting, OEA levels may not reach the levels necessary to satisfy appetite. OEA is also a PPAR-α agonist, reducing appetite and stimulating lipolysis. Finally, it also enhances thermogenesis in both white adipose tissue and brown adipose tissue.

Each bottle of Olympus Labs ASSASS1NATE contains 30 servings of 4 capsules each, containing seven potent ingredients for fat loss and nutrient partitioning. Take 2 capsules twice daily before your two highest carb meals of the day. Alternately, take 1 capsule 4x/day before meals. Do not exceed 4 capsules per day.



There are no reviews yet.

Be the first to review “Olympus Labs ASSASS1NATE”

Your email address will not be published. Required fields are marked